Literature DB >> 29124399

Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study.

Iñigo Les1, Naiara Parraza2,3, Pilar Anaut4, Saioa Eguiluz4, Cristina Sánchez4, María Enriqueta Preciado5, Jesús Ángel Loza6, Ander Andía4.   

Abstract

To investigate the association of age and other factors with thrombosis risk in antiphospholipid antibody (aPL) carriers, a retrospective observational study was conducted in a cohort of patients with medium-high aPL titres recruited in a tertiary care hospital. Assuming an age difference of 9.8 years between patients with and without thrombosis, we estimated that a sample size of 70 participants was required. Several variables besides age including gender, vascular risk factors, inherited thrombophilias, non-thrombotic clinical manifestations, laboratory parameters, aPL profile, length of aPL exposure, antithrombotic drugs and partial aPL score were assessed by univariate analysis followed by multivariate logistic regression. Outcomes were analysed by whether thromboses occurred before (model 1) or after (model 2) aPL detection. Seventy patients [50 females; median (interquartile range) baseline age: 46.99 (39.39-66.20) years] were followed for 2.59 (0.67-5.86) years. Overall, 18 and 5 thromboses were diagnosed applying models 1 and 2, respectively. Time to thrombosis after aPL detection was 2.10 (1.03-8.24) years. Age did not differ between patients with and without thrombosis using models 1 (p = 0.92) or 2 (p = 0.67). Instead, we identified other predictors of thrombosis, namely, lack of thromboprophylaxis [odds ratio (OR) 13.50, 95%  confidence interval (95% CI) 1.02-178.05, p = 0.048] and length of aPL exposure (OR 1.41, 95% CI 1.04-1.92, p = 0.026) in model 2, while lupus anticoagulant showed a tendency to increase the risk (OR 7.10, 95% CI 0.86-58.78, p = 0.069) in model 1. Unlike age, lack of thromboprophylaxis, prolonged aPL exposure and lupus anticoagulant may increase the risk of thrombosis in aPL carriers.

Entities:  

Keywords:  Age factors; Antibodies; Antiphospholipid; Risk factors; Thrombosis

Mesh:

Substances:

Year:  2017        PMID: 29124399     DOI: 10.1007/s00296-017-3878-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  44 in total

Review 1.  Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons".

Authors:  Fulvia Ceccarelli; Cecilia Chighizola; Guido Finazzi; Pier Luigi Meroni; Guido Valesini
Journal:  Autoimmun Rev       Date:  2011-10-22       Impact factor: 9.754

2.  Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction.

Authors:  P Soltesz; H Der; K Veres; R Laczik; S Sipka; G Szegedi; P Szodoray
Journal:  Rheumatology (Oxford)       Date:  2008-09-09       Impact factor: 7.580

Review 3.  Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review.

Authors:  Savino Sciascia; Giovanni Sanna; Veronica Murru; Dario Roccatello; Munther A Khamashta; Maria Laura Bertolaccini
Journal:  Thromb Haemost       Date:  2013-10-31       Impact factor: 5.249

Review 4.  Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence.

Authors:  Gabriela Medina; Eduardo Briones-García; María Pilar Cruz-Domínguez; Oscar I Flórez-Durante; Luis J Jara
Journal:  Autoimmun Rev       Date:  2017-02-13       Impact factor: 9.754

5.  Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36.

Authors:  S Georgopoulou; S Efraimidou; S J MacLennan; F Ibrahim; T Cox
Journal:  Lupus       Date:  2014-09-19       Impact factor: 2.911

6.  Real world experience with antiphospholipid antibody tests: how stable are results over time?

Authors:  D Erkan; W J M Derksen; V Kaplan; L Sammaritano; S S Pierangeli; R Roubey; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2005-02-24       Impact factor: 19.103

7.  Longitudinal study of antinuclear and anticardiolipin antibodies in pregnant women with systemic lupus erythematosus and antiphospholipid syndrome.

Authors:  Mario Salazar-Páramo; Luis J Jara; Azucena Ramos; Leonor Barile; Guadalupe Machado; Ignacio García-De La Torre
Journal:  Rheumatol Int       Date:  2002-06-19       Impact factor: 2.631

8.  Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.

Authors:  Adriana Danowski; Mario Newton Leitão de Azevedo; Jose Angelo de Souza Papi; Michelle Petri
Journal:  J Rheumatol       Date:  2009-05-15       Impact factor: 4.666

9.  The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome.

Authors:  Gabriela Hernández-Molina; Grissel Espericueta-Arriola; Antonio R Cabral
Journal:  Clin Exp Rheumatol       Date:  2013-01-10       Impact factor: 4.473

10.  Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.

Authors:  Johanna Gustafsson; Iva Gunnarsson; Ola Börjesson; Susanne Pettersson; Sonia Möller; Guo-Zhong Fei; Kerstin Elvin; Julia F Simard; Lars-Olof Hansson; Ingrid E Lundberg; Anders Larsson; Elisabet Svenungsson
Journal:  Arthritis Res Ther       Date:  2009-12-10       Impact factor: 5.156

View more
  2 in total

1.  Evaluation of Frequency, Clinical Correlation, and Antibodies Confirmation Profile in Patients with Suspected Antiphospholipid Syndrome.

Authors:  Filipe F Martins; Teresa M L Campos
Journal:  TH Open       Date:  2021-10-19

2.  Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time in a patient with Hashimoto thyroiditis-associated thyroid cancer: A case report.

Authors:  Yuhong Zhong; Biyong Yan; Zhongqi Yu; Lin Wang
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.